Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

8.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.5K
Structure and Function of Platelets01:18

Structure and Function of Platelets

2.7K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.7K
Introduction to Hemostasis01:05

Introduction to Hemostasis

12.7K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
12.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

981
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
981
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

8.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a Rapid-Acting Oxidized Regenerated Cellulose-Based Powder for Hemostatic Applications.

ACS omega·2026
Same author

Developmentally Inspired, Mechanical-Metabolic Dual Gradient Osteochondral Constructs Bridging Regeneration and Therapeutic Screening.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Scattering Coefficient Estimation Using Thin-Film Phantoms with a Spectral-Domain Dental OCT System.

Sensors (Basel, Switzerland)·2026
Same author

Bidirectional Mechanical Stimulation Enables Biomechanical Coupling and Functional Maturation in Arterial Microphysiological Systems.

Advanced healthcare materials·2026
Same author

Strategies to Screen and Evaluate Brain Targeting Antibodies Using an iPSC-Derived Blood-Brain Barrier Model.

Antibodies (Basel, Switzerland)·2025
Same author

Peptide-Catalyzed Asymmetric Amination of Sulfenamides Enabled by DFT-Guided Catalyst Optimization.

Journal of the American Chemical Society·2025

Related Experiment Video

Updated: Dec 28, 2025

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.1K

Activated Platelet-Derived Vesicles for Efficient Hemostatic Activity.

Joo Hang Lee1, Heesun Jung1, Jihyeon Song1

  • 1Department of Bioscience and Biotechnology, Konkuk University, Seoul, 143-701, Republic of Korea.

Macromolecular Bioscience
|February 14, 2020
PubMed
Summary

Activated platelet-derived vesicles (Act-VEs) show promise as a novel hemostatic biomaterial. These Act-VEs efficiently form fibrin clots and reduce bleeding in vivo with lower pro-inflammatory cytokine release compared to platelets.

Keywords:
activated platelet-derived vesiclesfibrin clothemostasisinflammatory cytokineplatelet activationplatelet-derived vesicles

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.8K
An In Vitro Assay to Study Platelet Migration Using RGD-Functionalized Avidin-Biotin Tethers
05:43

An In Vitro Assay to Study Platelet Migration Using RGD-Functionalized Avidin-Biotin Tethers

Published on: November 8, 2024

710

Related Experiment Videos

Last Updated: Dec 28, 2025

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.1K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.8K
An In Vitro Assay to Study Platelet Migration Using RGD-Functionalized Avidin-Biotin Tethers
05:43

An In Vitro Assay to Study Platelet Migration Using RGD-Functionalized Avidin-Biotin Tethers

Published on: November 8, 2024

710

Area of Science:

  • Biomaterials Science
  • Hematology
  • Nanotechnology

Background:

  • Platelet-derived vesicles (VEs) are investigated for hemostatic applications.
  • Activated platelet-derived vesicles (Act-VEs) offer potential as advanced biomaterials.
  • Understanding vesicle surface characteristics is crucial for hemostatic efficacy.

Purpose of the Study:

  • To develop and characterize activated platelet-derived vesicles (Act-VEs) as a novel hemostatic biomaterial.
  • To evaluate the fibrin clot formation and in vivo hemostatic performance of Act-VEs.
  • To assess the inflammatory potential of Act-VEs compared to native platelets.

Main Methods:

  • Preparation of spherical Act-VEs from thrombin-activated murine platelets.
  • Characterization of vesicle size, surface charge, and protein expression (GP IIb/IIIa, P-selectin).
  • Assessment of aggregation, fibrinogen incubation, in vivo bleeding time, blood loss, and IL-1β release.

Main Results:

  • Act-VEs were successfully prepared with specific size and surface charge, exhibiting high expression of active GP IIb/IIIa and P-selectin.
  • Act-VEs formed larger aggregates and denser fibrin networks compared to VEs and platelets, attributed to active GP IIb/IIIa.
  • In vivo studies showed Act-VEs significantly reduced tail bleeding time and blood loss, with substantially lower IL-1β release than platelets.

Conclusions:

  • Formulated Act-VEs demonstrate potent hemostatic capabilities through efficient fibrin clot formation.
  • Act-VEs represent a promising biomaterial for hemorrhage control with reduced pro-inflammatory response.
  • The active GP IIb/IIIa on Act-VEs is key to their enhanced fibrin network formation and hemostatic efficacy.